Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
Received date: May 23, 2016; Accepted date: June 06, 2016; Published date: June 10, 2016
Citation: Gao Y, Liu H, Hu P, Chen M, Tian X, et al. (2016) The Pharmacokinetics and Metabolism of Neomangiferin, a Major Bioactive Component in Anemarrhena asphodeloides. Med chem (Los Angeles) 6:385-394. doi:10.4172/2161-0444.1000374
Copyright: © 2016 Gao Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Medicinal Chemistry
As a natural derivative of bioactive xanthone mangiferin, neomangiferin exhibits a wide spectrum of bioactivities. However, studies have yet to elucidate the metabolic pathways and pharmacokinetics of orally administered neomangiferin in vivo. In this study, a simple and accurate high-performance liquid chromatography/diode array detector method was developed and validated to simultaneously determine neomangiferin and its active metabolite mangiferin in plasma after oral and intravenous administration of neomangiferin to rats. Chromatographic separation was performed in a C18 column by using water containing 0.1% formic acid-acetonitrile (88:12, v/v) at a flow rate of 0.7 mL/min. The calibration curves of neomangiferin and mangiferin in rat plasma were linear at 150-15000 (r=0.9999) and 50-1500 ng/mL (r=0.9994), respectively. The relative standard deviations of intraday and inter-day precision were below 10.7%, and accuracy ranged from 94.0 to 105.5% for both analytes. Experimental results showed that intravenously and orally administered neomangiferin was partly metabolized into mangiferin. Tmax of neomangiferin and mangiferin was low (0.05 h), and the two components were eliminated at t1/2 of 0.95 and 0.73 h, respectively. Similar to that of mangiferin, the oral bioavailability of neomangiferin was also low (about 0.32%). Thirty-three metabolites were detected and absolutely or tentatively identified on the basis of mass spectral fragmentation pattern and elution order or were confirmed by using available reference standards. Our findings suggested that neomangiferin undergoes rapid and extensive phases I and II metabolic processes, such as deglycosylation, dehydroxylation, methylation, glycosylation, glucuronidation, and sulfation, in rats. In general, the pharmacokinetic and metabolic profiles, including poor bioavailability, high absorption and elimination rates, extensive biotransformation, of neomangiferin are similar to those of mangiferin to some degrees.
Neomangiferin; Mangiferin; Pharmacokinetics; Metabolism; HPLC-DAD
As a derivative of bioactive xanthone mangiferin, neomangiferin (Figure 1) is a natural xanthone C-glycoside mainly obtained from the well-known traditional Chinese medicine rhizoma of Anemarrhena asphodeloides . This plant is officially listed in the Chinese Pharmacopeia under the name Zhimu. Various biological activities have been discovered in neomangiferin. For instance, neomangiferin exhibits antidiabetic activity in KK-Ay mice by decreasing insulin resistance and increasing insulin sensitivity [2,3]. Neomangiferin presents antiosteoporotic action in ovariectomized rats . It also elicits anti-colitic effects by suppressing IL-17 and RORγ t expression and inducing IL-10 and forkhead box P3 expression .
Neomangiferin and mangiferin co-exist, and they are considered the major active constituents in Zhimu . Mangiferin has been investigated extensively because of its remarkable pharmacological effects, including antioxidant [7,8], anti-inflammatory , antidiabetic , anticancer , antibacterial , anti-HIV , and radioprotective activities . Notably, neomangiferin is likely biotransformed to mangiferin in vivo .
With advanced knowledge of the pharmacological effects of neomangiferin and mangiferin, it is necessary to gain insights into the pharmacokinetic profiles in vivo because pharmacokinetics plays an increasingly crucial role in drug discovery and development processes; pharmacokinetics not only further supports toxicity or clinical trials but also optimizes drug candidates . The metabolism and pharmacokinetic profiles of mangiferin have recently been examined [16-18]. Pharmacokinetic studies have indicated that mangiferin exhibits poor oral bioavailability (1.2%) when orally administered with the isolated compound directly . However, very few studies have been published on the pharmacokinetics and metabolism of neomangiferin as another major bioactive substance and structurally similar to mangiferin. Ma et al.  bioanalyzed neomangiferin after Rhizoma Anemarrhenae decoction is orally administered. Qiu et al.  developed an ultra-performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS) method to simultaneously determine mangiferin and neomangiferin in rat plasma after co-administration of mangiferin and neomangiferin. However, the pharmacokinetics of orally administered neomangiferin and its active metabolite-mangiferin has yet to be reported. The biotransformation of neomangiferin in vivo also remains unknown.
In this study, a simple and accurate method was established to determine neomangiferin and its metabolite mangiferin in rat plasma simultaneously. The proposed method was successfully applied to analyze neomangiferin pharmacokinetically after it was orally and intravenously administered to rats. The metabolites of neomangiferin in rats systemically and comprehensively investigated through LC-ESI- IT-MSn to establish possible metabolic pathways. Our findings helped elucidate the therapeutic effects and mechanism of action of neomangiferin, and promote its further development.
Chemicals and reagents
Neomangiferin (98% purity) for dosing was purchased from Tianjin Zhongxin Pharmaceutical Group Corporation (Tianjin, China). Puerarin (for internal standard), neomangiferin, and mangiferin (for reference) were purchased from the National Institute for Control of Pharmaceutical and Biological Products (Beijing, China). Streptozotocin, streptomycin, and neomycin sulfate were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile and formic acid used for HPLC (HPLC grade) were purchased from Fisher Chemical Co., Inc. (CA, USA). All other analytical grade reagents were from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, P. R. China). Triple deionized water was prepared in a Milli-Q system (Millipore, Billerica, MA, USA) in our laboratory whenever necessary. Waters Oasis HLB cartridges (60 mg, 3 cm3) for sample pretreatment were purchased from Waters (Milford, MA).
Male Wistar rats (250 ± 10 g) were purchased from Shanghai SLAC Laboratory Animal Co. (Shanghai, China). All animals were housed in an environmentally controlled room and acclimated for one week before use.
For preparation of pseudo-germ-free animals, neomycin sulfate (100 mg/kg) and streptomycin (100 mg/kg) were orally administered to 10 conventional rats twice per day for 6 days. The experiments were performed 2 days after the final administration.
For metabolism and pharmacokinetic study, animals were divided into three drug-treated groups (ten healthy rats in group A after oral administration; ten healthy rats in group B after intravenous injection; ten pseudo-germfree rats in group C after oral administration; with five rats per group for urine and feces collecting and the rest for blood withdrawn) and one control group with six rats. All animals were fasted overnight with free access to water prior to a single oral dose (400 mg/kg) or intravenous injection (1.8 mg/kg). All animal studies were conducted according to protocols approved by the Review Committee of Animal Care and Use at the Shanghai Institute of MateriaMedica (Shanghai, China).
Instrumentation and analytical conditions
Quantification of neomangiferin and mangiferin in plasma: determination of neomangiferin and mangiferin in rat plasma was performed on an Agilent 1260 system (Agilent, Waldbronn, Germany) equipped with a quaternary pump, a photodiode array detector (DAD) working in the range of 190-400 nm, autosampler and a column compartment. The chromatographic separation was performed on an Inertsil ODS-3 column (150 mm × 4.6 mm, 5 μm, GL Sciences, Tokyo, Japan) protected with a guard column (10.0 mm × 4.6 mm, 5 μm, Dikma Technologies, Beijing, China) eluted at 0.7 mL/min with a mobile phase of acetonitrile-water containing 0.1% formic acid (12:88, v/v). The wavelength was set at 320 nm and the column temperature was kept at 25°C. The injection volume was 20 μL. The chromatographic data were recorded and processed with Agilent ChemStation software.
Identification of neomangiferin metabolites in rat biological samples: separation was achieved on a reversed phase Inertsil ODS- 3 column (4.6 mm × 250 mm, 5 μm, GL Sciences, Tokyo, Japan) connected to a Diamonsil C18 guard column (2.1 mm × 12.5 mm, 5 m, Dikma Technologies, Beijing, China). The column temperature was set at 25°C and the flow rate maintained at 0.8 mL/min. Mobile phase consisting of acetonitrile (A) and water containing 0.5% formic acid (B) used a linearly gradient program as follows: 10-23% A at 0-15 min, hold for 5 min, linearly gradient to 45% A in 25 min, then linearly gradient to 61% A at 60 min. An aliquot of 20 μL of the purified sample was injected automatically into the HPLC system for LC-ESI-IT-MSn analysis. MSn analyses were conducted in negative ion mode and the operating parameters were optimized as follows: collision gas, ultrahigh-purity helium (He); nebulizing gas, high-purity nitrogen (N2); capillary voltage, 3.5 kV; end plate offset, 500 V; nebulizer, 30 psi; drying gas flow rate, 10 L/min; drying gas temperature, 350°C. For full scan MS analysis, the spectra were recorded in the range of 100-1000 Da.
Preparation of stock and working solutions
The standard stock solutions of neomangiferin, mangiferin, and puerarin were individually prepared in 50% methanol at 120 μg/mL and serially diluted to make the working solutions with 50% methanol. All stock and working solutions were stored at −20°C until use.
Preparation of calibration standards and quality control samples
Calibration standards samples were prepared by spiking appropriate amount of the standard solutions in blank plasma (200 μL) to yield final concentrations of 150, 300, 600, 1200, 3000, 6000, 15000 ng/mL for neomangiferin; 50, 100, 300, 600, 900, 1200, and 1500 ng/mL for mangiferin and 3000 ng/mL for puerarin. Three concentrations of quality control (QC) samples were prepared containing neomangiferin (300, 6000, and 12000 ng/mL), mangiferin (100, 600, and 1200 ng/mL), and puerarin (3000 ng/mL) in the same manner.
Plasma sample preparation
The plasma (200 μL, containing the IS at the concentration of 3000 ng/mL) was pretreated by protein precipitation with 3 volumes of acetonitrile-acetic acid (v/v, 9:1). The supernatant was separated and dried under nitrogen gas at 37°C after vortexing for 2 min and centrifuging at 15,000 g for 10 min. The residues were reconstituted in 100 μL of 50% methanol and centrifuged twice at 15,000 g for 10 min. A 20 μL aliquot was injected into the HPLC-DAD system for analysis.
This assay was validated by validating specificity, lower limit of quantification (LLOQ), linearity, accuracy, precision, recovery, and stability.
Specificity was evaluated by analyzing blank plasma samples from six different sources to investigate the potential interferences for the analytes and IS. The linearity for each analyte (neomangiferin and mangiferin) was determined by plotting the peak area ratios of the analyte to the IS against the concentrations of neomangiferin and mangiferin in plasma in duplicate on five consecutive validation days.
The lowest limit of quantitation (LLOQ) of the assay was determined as the lowest concentration on the standard curve that could be reliably detected and reproducible with a precision equal to or less than 20% and accuracy between 80% and 120%.
The precision and accuracy of the method were assessed by replicate analysis (n=5) of QC samples on the same day (intra-day) and also on five consecutive days (inter-day). The intra- and inter-day precisions were required to be below 15%, and the accuracy within ± 15%.
The extraction recovery of neomangiferin, mangiferin and IS (puerarin) was determined by comparing peak areas obtained after whole extraction of QC samples at three concentration levels for five replicates with those obtained from direct injections of standard solutions.
The stability of neomangiferin and mangiferin in rat plasma was assessed by analyzing three replicates of QC samples (n=3) at three concentrations. The stability of 24 h was performed by the QC samples during analysis at room temperature. Long-term stability was tested after storage of samples at −80°C for 25 days. The freeze/thaw stability was examined at three freeze/thaw cycles between −80°C and room temperature. Samples were considered stable with the deviation from the nominal concentration within ± 15%.
The validated HPLC-DAD method was applied to simultaneously determine the plasma concentrations of neomangiferin and mangiferin in healthy rats after oral administration and intravenous injection of neomangiferin. Blood samples were withdrawn via the angular vein at 20 min, 40 min, 70 min, 2 h, 3 h, 4 h, 5 h, 6.5 h, 8 h, 9.5 h, 11 h, and 24 h after oral administration and 3, 6, 10, 20, 30, 45, 60, 90, 120, and 180 min after intravenous injection. Plasma was separated from blood placed in heparinized Eppendorf tubes after centrifuging at 4000 × g for 10 min. All plasma samples were stored at −80°C until analysis. Pharmacokinetic analysis was performed with WinNonlin software (Pharsight 6.2; NC, USA) utilizing non-compartmental analysis.
Metabolism study of neomangiferin
Urine and feces samples within 0-48 h post-treatment were collected and admixed separately. Plasma samples at each time point were combined for metabolic study after pharmacokinetic study. Each sample of urine (400 μL) and plasma (400 μL) was loaded onto a SPE column preconditioned with 3 mL of methanol and 3 mL of water subsequently. The cartridge was then washed with 3 mL of water and the analytes were eluted with 2 mL of methanol. Feces sample (50 mg) was extracted by ultrasonication three times with 1 mL of methanol for 30 min each time. Drug containing plasma was precipitated with 3 volumes of acetonitrile: acetic acid (9:1). The supernatant was separated after votexing and centrifuging. Extracting solutions with different pretreatment methods described above were all dried under nitrogen gas over a water bath of 37°C. The residues were reconstituted in 100 μL of methanol and centrifuged twice at 10,000 × g for 10 min prior to analysis. All the blank samples as control were prepared with the same method as drug containing samples.
The representative chromatograms obtained from blank plasma, blank plasma spiked with the analytes and IS, and plasma sample after administration are shown in Figure 2. Neither endogenous interference nor metabolites appeared at the retention time of the analytes and IS. The retention time of neomangiferin, IS (puerarin) and mangiferin were 7.5, 18.5 and 20.7 min, respectively.
The calibration curves of neomangiferin and mangiferin in rat plasma were linear over the ranges 150-15000 and 50-1500 ng/ mL, respectively. The regression equations were y=0.0005x−0.0234 (r=0.9999) for neomangiferin and y=0.0009x+0.0115 (r=0.9994) for mangiferin. The lowest limit of Quantitation (LLOQ) of neomangiferin and mangiferin in rat plasma were 150 and 50 ng/mL, respectively.
The estimates of the intra- and inter-day precision and accuracy of the assay are presented in Table 1. For all the QC samples spiked with analytes at three concentration levels in rat plasma, the relative standard deviations (RSD) for both intra-day and inter-day precision were below 10.7%, and the accuracy was within the range of 94.0%- 105.5% for both analytes.
|Mean ± SD||Accuracy (%)||RSD
|Mean ± SD||Accuracy (%)||RSD
|neomangiferin||300||302.08 ± 13.90||100.7||4.6||300.85 ± 27.79||100.3||9.2||56.6 ± 2.3|
|6000||5640.45 ± 238.99||94.0||4.2||6067.74 ± 649.18||101.1||10.7||61.2 ± 3.2|
|12000||11694.2 ± 151.65||97.5||1.3||12219.85 ± 1032.6||101.8||8.4||59.8 ± 1.9|
|mangiferin||100||100.15 ± 2.12||100.2||2.1||105.55 ± 6.54||105.5||6.2||77.8 ± 5.1|
|600||583.36 ± 13.38||97.2||2.3||577.64 ± 7.41||96.3||1.3||81.5 ± 1.7|
|1200||1213.36 ± 57.14||101.1||4.7||1195.51 ± 20.64||99.7||1.7||75.0 ± 2.5|
Table 1: Intra- and inter-day precision, accuracy and recovery for determination of neomangiferin and mangiferin in plasma (n=5).
The extraction recoveries were 56.6% ± 2.3%, 61.2% ± 3.2%, 59.8% ± 1.9% for neomangiferin and 77.8% ± 5.1%, 81.5% ± 1.7%, 75.0% ± 2.5% for mangiferin at three concentrations, respectively. Recovery for the internal standard was 75.8% ± 2.9%.
Table 2 suggests that the analytes were stable in plasma samples for 24 h at room temperature after preparation, within three freeze-thaw cycles, and after storage at −80°C for 25 days.
|Condition||Neomangiferin (Stability (%) ± SD)||Mangiferin (Stability (%) ± SD)|
|300 (ng/ml)||6000 (ng/ml)||12000 (ng/ml)||100 (ng/ml)||600 (ng/ml)||1200 (ng/ml)|
|Short term stability||101.46 ± 0.43||103.03 ± 3.10||100.27 ± 0.91||99.61 ± 8.11||100.16 ± 2.49||93.91 ± 1.11|
|Freeze–thaw stability||96.94 ± 6.41||99.15 ± 4.64||98.07 ± 5.82||95.51 ± 9.85||104.03 ± 7.27||100.89 ± 1.19|
|Long term stability||98.64 ± 1.94||101.86 ± 2.47||101.31 ± 7.69||100.16 ± 6.16||95.61 ± 2.15||103.06 ± 3.3|
Table 2: Assessment of stability of neomangiferin and mangiferin in plasma (n=3).
The concentration-time profiles of neomangiferin and its metabolite mangiferin in rat plasma following intravenous and oral neomangiferin administration are presented in Figure 3, and the selected pharmacokinetic parameters are summarized in Table 3.
Figure 3: Mean plasma concentration-time profiles of (A) neomangiferin after neomangiferin was intravenously injected to rats, (B) mangiferin after neomangiferin was intravenously injected to rats, (C) neomangiferin after neomangiferin was orally administered to rats, and (D) mangiferin after neomangiferin was orally administered to rats (each point represents mean ± SE, n=5).
|Parameter||Healthy rats (i.v.)||Healthy rats (p.o.)|
|Cmax (ng/mL)||10817.9 ± 1089.7||899.48 ± 64.71||1804.28 ± 818.15||824.48 ± 115.74|
|Tmax (h)||0.05||0.05||0.67||1.54 ± 0.82|
|t1/2 (h)||0.95 ± 0.06||0.73 ± 0.15||0.95 ± 0.31||3.22 ± 1.07|
|AUC0–t (ng h/mL)||4372.03 ± 658.52||392.78 ± 54.98||3107.96 ± 1117.93||3276.08 ± 500.96|
|AUC0–∞ (ng h/mL)||4578.82 ± 680.4||411.52 ± 64.66||3333.86 ± 1147.37||3758.04 ± 448.14|
|MRT0–t (h)||0.54 ± 0.01||0.59 ± 0.06||1.38 ± 0.13||3.27 ± 0.16|
|MRT0–∞ (h)||0.72 ± 0.02||0.74 ± 0.13||1.69 ± 0.19||4.79 ± 1.57|
|CL/CL_F (L/kg/h)||0.4 ± 0.06||4.46 ± 0.69||132.43 ± 46.6)||107.73 ± 13.57|
Table 3: Pharmacokinetic parameters of the neomangiferin and mangiferin in rats after oral administration (p.o.) or intravenous administration (i.v.) of neomangiferin (mean ± SD, n=5).
After its intravenous administration, neomangiferin was partly metabolized into mangiferin rapidly and resulted in the increase of mangiferin in plasma, which was detected in the plasma from the first plasma sampling time (3 min). Neomangiferin and mangiferin rapidly reached Tmax (0.05 h). The Cmax of neomangiferin reached 10817.9 ng/ mL, whereas the Cmax of the formed mangiferin reached 899.48 ng/mL. Neomangiferin was eliminated at a t1/2 of 0.95 h, whereas mangiferin was eliminated at 0.73 h. The parent compound was detected in the plasma samples up to 180 min, whereas the concentration of mangiferin was below the lowest limit of quantitation (LLOQ) after 90 min. Compared with the pharmacokinetic parameters of neomangiferin and mangiferin in a previous publication , neomangiferin showed similar clearance after the sole intravenous administration of neomangiferin or the coadministration of neomangiferin and mangiferin. This finding indicates that the plasma clearance of neomangiferin may not be affected by the combinational administration of structurally similar xanthonoids. The area under the curve (AUC0-∞) of neomangiferin, calculated as 4578.82 ± 680.4 (ng h)/mL, was about 11.14 fold higher than that of mangiferin (411.52 ± 64.66 (ng h)/mL).
When neomangiferin was orally administered to healthy rats, neomangiferin absorption and mangiferin formation were rapid; neomangiferin and mangiferin were detected in the plasma from the first plasma sampling time (20 min) and reached the maximum concentration shortly afterward (Tmax 0.67 h for neomangiferin and 1.54 h for mangiferin). This finding is consistent with that in a previous study in which neomangiferin was absorbed promptly at a Tmax of 0.58 h after oral administration of the Zi-Shen Pill extract . The Cmax of neomangiferin reached 1804.28 ng/mL, whereas the t1/2 was only 0.95 ± 0.31 h, which is much lower than the corresponding value obtained after the oral administration of the Zi-Shen Pill . The Cmax of mangiferin was 824.48 ng/mL, and the plasma concentration slowly declineds with a relatively long elimination t1/2 of 3.22 h. Hence, the elimination rate of mangiferin was slower than that of neomangiferin. Given the corresponding AUC0-∞, the parent-to-metabolite exposure ratio was calculated to be about 1.12, which is lower than that of intravenous administration (11.14). This result indicates that a certain amount of neomangiferin could be transformed to its metabolite mangiferin in the gastrointestinal tract and subsequently absorbed in vivo. Notably, the AUC0-∞ of the formed mangiferin in plasma was relatively high compared with that of the parent drug neomangiferin (AUCneomangiferin/ AUCmangiferin=1.12). Given the slow elimination rate of mangiferin, such AUC suggests that the active metabolite mangiferin appears to determine neomangiferin activity after oral administration. The oral bioavailability of neomangiferin was only 0.32%, which is similar to that of mangiferin. These phenomena might be attributed to the low absorption and extensive metabolism of neomangiferin in vivo. Generally, neomangiferin exhibited rapid excretion and extremely low plasma concentration in the rats.
Metabolic study of neomangiferin
Neomangiferin-dosed biological samples were analyzed in parallel with corresponding blank controls using the developed LC-ESI-IT- MSn method. A total of 33 metabolites were detected and were further structurally identified. The extracted ion chromatograms of neomangiferin and its metabolites are presented in Figure 4. The identified compounds are summarized in Table 4.
|Data-dependent MSn data(% base peak)
|M0||neomangiferin||11.4||+||+||-||+||+||-||+||+||-||583[M-H]-||MS2: 565(28), 493(100), 463(61), 421(12), 331(9), 301(7)
MS3 : 403(19), 331(65), 301(100)
|M1||mangiferin glucuronide||11.2||-||-||-||-||-||-||-||+||-||597[M-H]-||MS2 : 421(100), 331(6), 301(11)
MS3 : 403(12), 331(73), 301(100), 259(9)
|M2||mangiferin glucuronide||12.2||-||-||+||-||+||-||-||+||-||597[M-H]-||MS2 : 579(39), 507(60), 477(65), 421(100), 331(79), 301(55)
MS3 : 403(15), 331(100), 301(80)
|M3||monomethyl mangiferin glucuronide||12.8||-||-||-||-||+||-||-||+||-||611[M-H]-||MS2: 593(7), 521(3), 491(12), 435(100), 345(5), 315(25), 272(3)
MS3 : 417(4), 345(43), 315(100), 272(11)
|M4||monomethyl mangiferin glucuronide||13.5||-||-||-||-||+||-||-||+||-||611[M-H]-||MS2 : 435(100), 345(7), 315(9)
MS3 : 417(12), 345(59), 315(100), 273(3)
|M5||mangiferin||16.1||+||-||+||+||+||+||+||+||+||421[M-H]-||MS2 : 403(17), 331(73), 301(100)
MS3 : 259(93)
|M6||monomethyl mangiferin||17.5||-||-||+||-||-||+||-||-||-||435[M-H]-||MS2 : 345(3), 315(100), 287(44), 272(28)
MS3 : 259(100), 272(1)
|M7||norathyriol diglucuronide||17.8||-||-||-||-||+||-||-||-||-||611[M-H]-||MS2 : 435(100), 259(12)
MS3 : 259(100)
|M8||norathyriol glycoside glucuronide||18.3||-||-||-||-||+||-||-||-||-||597[M-H]-||MS2 : 435(100), 417(61), 259(23)
MS3 : 259(100)
|M9||norathyriol glycoside glucuronide||19.0||-||-||-||-||+||-||-||-||-||597[M-H]-||MS2 : 421(100), 259(4)
MS3 : 259(100)
|M10||monomethyl mangiferin||19.9||-||-||+||-||+||-||-||-||+||435[M-H]-||MS2 : 417(4), 345(12), 315(100), 272(14), 259(18)
MS3 : 315(100), 272(6)
|M11||norathyriol diglucuronide||20.2||-||-||-||-||+||-||-||-||-||611[M-H]-||MS2 : 435(100), 258(5)
MS3 : 259(100)
|M12||monomethyl mangiferin||20.9||-||+||+||+||+||+||-||-||+||435[M-H]-||MS2 : 417(5), 345(30), 315(100), 272(8)
MS3 : 272(3)
|M13||monomethyl norathyriol diglucuronide||21.3||-||-||-||-||+||-||-||-||-||625[M-H]-||MS2 : 449(100), 273(50)
MS3 : 273(100)
MS4 : 258(4)
|M14||mangiferin sulfate||22.1||-||-||-||-||-||-||-||-||+||501[M-H]-||MS2 : 421(100), 301(4)
MS3 : 403(12), 331(93), 301(100), 259(7)
|M15||norathyriol glycoside||25.5||-||-||-||-||+||-||-||-||-||421[M-H]-||MS2 : 259(100)|
|M16||dimethyl mangiferin||25.6||-||-||-||-||+||-||-||-||-||449[M-H]-||MS2 : 345(5), 315(18), 273(100)
MS3 : 258(16)
|M17||monodehydroxyl norathyriol glucuronide||25.7||-||-||-||-||+||-||-||-||-||419[M-H]-||MS2 : 243(100)|
|M18||dimethyl mangiferin||26.2||-||-||-||-||+||-||-||-||-||449[M-H]-||MS2 : 315(4), 273(100)
MS3 : 258(23)
|M19||norathyriol glucuronide||27.5||-||-||-||+||+||-||-||-||-||435[M-H]-||MS2 : 259(100)|
|M20||monodehydroxyl norathyriol glucuronide||27.9||-||-||-||-||+||-||-||-||-||419[M-H]-||MS2 : 243(100)|
|M21||monomethyl mangiferin sulfate||28.0||-||-||+||+||-||-||+||+||+||515[M-H]-||MS2 : 435(100), 345(5), 315(5)
MS3 : 417(19), 345(59), 315(100)
|M22||monomethyl norathyriol glucuronide||28.2||-||-||-||-||+||-||-||-||-||449[M-H]-||MS2 : 273(100), 258(30)
MS3 : 258(52)
|M23||norathyriol glucuronide||28.6||-||-||-||+||+||-||-||-||-||435[M-H]-||MS2 : 259(100)|
|M24||monodehydroxyl norathyriol glucuronide||28.7||-||-||-||-||+||-||-||-||-||419[M-H]-||MS2 : 243(100)
MS3 : 199(3)
|M25||monomethyl norathyriol glucuronide||30.6||-||-||-||+||+||-||-||-||-||449[M-H]-||MS2 : 273(100)
MS3 : 258(19)
|M26||didehydroxyl norathyriol glucuronide||32.2||-||-||-||-||+||-||-||-||-||403[M-H]-||MS2 : 227(100)|
|M27||monomethyl norathyriol glucuronide||33.1||-||-||-||+||+||-||-||-||-||449[M-H]-||MS2 : 273(100)
MS3 : 258(10)
MS3 : 231(9)
|M28||norathyriol||37.4||-||-||-||-||+||+||-||-||-||519[2M-H]-||MS2 : 259(100)
MS3 : 231(1)
|M29||norathyriol glycoside sulfate||38.1||-||-||-||-||+||-||-||-||-||501[M-H]-||MS2 : 421(100), 259(100)
MS3 : 258(100)
|M30||monomethyl norathyriol||43.8||-||-||-||-||+||-||-||-||-||273[M-H]-||MS2 : 258(100)
MS3 : 230(1)
|M31||monodehydroxyl norathyriol||44.9||-||-||-||-||+||+||-||-||-||243[M-H]-||MS2 : 199(100)|
|M32||monomethyl norathyriol||46.4||-||-||-||-||+||+||-||-||-||273[M-H]-||MS2 : 258(100)
MS3 : 230(9)
|M33||monomethyl norathyriol||51.9||-||-||-||-||-||+||-||-||-||273[M-H]-||MS2 : 258(100)|
Table 4: Retention time, identification, detection, and MSn data of neomangiferin and its metabolites.
Metabolites (M0, M5, M28, and M34) were unambiguously identified as neomangiferin, mangiferin, norathyriol, and 1,7-dihydroxanthone, respectively, by comparing the characteristics of the fragmentation patterns and retention times with those of the standard compound. By contrast, the structures of 30 other metabolites (M1-M4, M6-M27, and M29-M33) were tentatively ascertained.
Metabolites M1 and M2 were eluted at 11.2 and 12.2 min, respectively. Both of the compounds showed similar [M−H]- ions at m/z 597, and their MS2 spectra yielded a major fragment at m/z 401 because of the loss of a glucuronide moiety (176 Da). The MS3 spectral spectrum of m/z 421 released product ions at m/z 403, 331, and 301; these ions were characteristic of mangiferin. Generally, in reversed phase HPLC, the more sugar moieties attached, the earlier the retention time. The earlier retention times of M1 and M2 are in keeping with them being mangiferin conjugated with one glucuronide. Therefore, the two metabolites were tentatively assigned as isomers of mangiferin glucuronide.
Metabolites M3 and M4 were detected at 12.8 and 13.5 min, respectively. The two metabolites afforded an [M−H]- ion at m/z 611, which was 14 Da higher than those of M1 and M2. The characteristic MS2 product ions at m/z 593, 521, 491, 435, 345, and 315 all increased by 14 Da compared with those of M1 and M2. This observation suggests the addition of a methyl group to the mangiferin glucuronide moiety. The addition of a methyl moiety to mangiferin glucuronide markedly increases reverse phase HPLC retentions. Thus, the two metabolites were identified as isomers of monomethyl mangiferin glucuronide.
The retention times of M6, M10, and M12 were 17.5, 19.9, and 20.9 min, respectively. The metabolites showed similar [M−H]- ions at m/z 435, which was 14 Da higher than that of mangiferin and corresponded to the methyl conjugate of mangiferin. The MS2 fragmentation ions at m/z 345, 315, 287, and 272 all increased by 14 Da compared with those of mangiferin. Because of the methyl attached, they eluted at a much later point than that of mangiferin. These results indicate that M6, M10, and M12 were isomers of monomethyl mangiferin.
M7 and M11, eluted at 17.8 and 20.2 min, respectively, each showed a [M−H]- ion at m/z 611. The MS2 fragmentation displayed characteristic fragment ions at m/z 435 and 259 derived from the successive loss of two glucuronide moieties. Together with the results of previous studies , we unambiguously identified M7 and M11 as the isomers of norathyriol diglucuronide.
M8 and M9, eluted at the retention time of 18.3 and 19.0 min, were detected with a [M−H]- ion at m/z 597. The MS2 spectrum of M8 displayed typical fragment ions at m/z 435 and 259, which resulted from the stepwise loss of a hexose and a glucuronide unit. The MS2 fragmentation of M9 was similar to that of M8, suggesting that M8 and M9 were isomers. Thus, M8 and M9 were tentatively identified as the isomers of norathyriol glycoside glucuronide.
M13, eluted at 21.3 min retention time, was detected with a [M−H]- ion at m/z 625. The MS2, MS3, and MS4 fragmentations showed characteristic fragment ions at m/z 449, 273, and 258 derived from the successive loss of two glucuronide and one monomethyl group. Therefore, the M13 was tentatively identified as monomethyl norathyriol diglucuronide.
M14, eluted at 22.1 min, displayed a [M−H]- ion at m/z 501, which was 80 Da higher than that of mangiferin. The MS2 fragmentation revealed a fragment ion at m/z 421, which was formed by the loss of a sulfate group. The MS/MS spectrum of m/z 401 released product ions at m/z 403, 331, 301, and 259, which were the characteristic ions of mangiferin. Therefore, the M14 was tentatively identified as mangiferin sulfate.
M15, present at 25.5 min, showed a [M−H]- ion at m/z 421, which was 162 Da higher than that of norathyriol. The MS2 fragmentation showed a fragment ion at m/z 259 derived from the loss of a glycoside unit. Comparison with norathyriol, M15 showed lower retention time. Therefore, the M15 was tentatively identified as norathyriol glycoside.
M16 and M18, eluted at retention times 25.6 and 26.2 min, showed a [M−H]- ion at m/z 449, which was 28 Da higher than that of mangiferin. The MS2 fragmentation ions at m/z 345, 315, and 273 all increased by 28 Da compared with those of mangiferin. The MS/ MS spectrum at m/z 273 provided a product ion at m/z 403, which was formed by the loss of a dimethyl group. Due to the dimethyl conjugated, M16 and M18 showed higher retention time than the monomethyl mangiferin. Therefore, the two metabolites were tentatively identified as isomers of dimethyl mangiferin.
M19 and M23, eluted at retention times 27.5 and 28.6 min, showed a [M−H]- ion at m/z 435, which was 176 Da higher than that of norathyriol. The fragment ion at m/z 259 was formed by the loss of a glucuronide group. Therefore, the two metabolites were tentatively identified as isomers of norathyriol glucuronide.
M17, M20, and M24, eluted at retention times 25.7, 27.9, and 28.7 min, showed a [M−H]- ion at m/z 419. The fragment ion at m/z 243 was formed by the loss of a glucuronide group. Previous experimental results confirmed the existence of monodehydroxylated and didehydroxylated metabolites of norathyriol in rat urine sample after oral administration of mangiferin . Therefore, M17, M20, and M24 were tentatively identified as isomers of monodehydroxyl norathyriol glucuronide.
M21, eluted at 28.0 min retention time, was detected with a [M−H]- ion at m/z 515. The fragment ion at m/z 435 was formed by the loss of a sulfate group. The MS3 product ions at m/z 417, 345, and 315 were the same as those of M6, M10, or M12, indicating that M21 was the further sulfated conjugate of M6, M10, or M12. M21 showed higher retention time than mangiferin sulfate. Therefore, M21 was tentatively identified as monomethyl mangiferin sulfate.
M22, M25, and M27, eluted at retention times 28.2, 30.6, and 33.1 min, similarly showed a [M−H]- ion at m/z 449, which was 14 Da higher than that of M19 or M23. The MS2 fragmentation ions at m/z 273 was increased by 14 Da compared with those of M19 or M23, suggesting that the metabolites were the further methylated forms of M19 or M23. Therefore, M22, M25, and M27 were tentatively identified as isomers of monomethyl norathyriol glucuronide.
M26, eluted at 32.2 min, showed a [M-H]- ion at m/z 403, which was 32 Da lower than that of M19 or M23, and corresponded to M19 or M23 with loss of two hydroxyl groups. The MS2 fragmentation showed fragment ions at m/z 227 because of the loss of a glucuronide group. The subtraction of hydroxyl groups to a norathyriol glucuronide moiety can cause it to elute later. Therefore, the metabolite was tentatively identified as didehydroxyl norathyriol glucuronide.
M26, eluted at retention time 38.1 min, showed a [M−H]- ion at m/z 501, which was 80 Da higher than that of M15. The MS2 fragmentation showed a fragment ion at m/z 421 because of the loss of a sulfate group. Therefore, the metabolite was tentatively identified as norathyriol glycoside sulfate.
M30, M32, and M33, eluted at retention times 43.8, 46.4, and 51.9 min, showed similar [M−H]- ions at m/z 273, which was 14 Da higher than that of norathyriol. The MS2 product ions at 258, was consistent with the ion observed in the MS3 spectra of M22, M25, or M27. Therefore, the metabolites were tentatively identified as isomers of monomethyl norathyriol.
M31, eluted at retention time 44.9 min, showed a [M−H]- ion at m/z 243, which was 16 Da lower than that of norathyriol. This observation revealed that M31 was a dehydroxyl product of norathyriol. And M31 have a longer retention time than the norathyriol. Therefore, the metabolite was tentatively identified as monodehydroxyl norathyriol.
Metabolism of neomangiferin in conventional rats
The proposed metabolic pathways of neomangiferin in conventional and pseudo-germ-free rats after its oral and intravenous injection administration are summarized in Figure 5.
After neomangiferin was intravenously injected to conventional rats, the parent compound could be detected in the plasma and urine. Furthermore, one metabolite (M5) in the plasma, one metabolite (M12) in the urine, and six metabolites (M2, M5, M6, M10, M12, and M21) in the feces were detected. In general, neomangiferin itself was initially deglycosylated to be transformed into mangiferin, which was further subjected to methylation to form the metabolites M6, M10, and M12, glucuronidation to form the metabolite M2 and sulfation to form the metabolite M21, respectively.
After neomangiferin was orally administered to conventional rats, neomangiferin underwent extensive metabolism in vivo to produce more metabolites. The parent compound and 7 metabolites (M5, M12, M19, M21, M23, M25, and M27) in plasma, the parent compound and 29 metabolites (M2-M5, M7-M13, M15-M20, M22-M32, and M34) in the urine, and 8 metabolites (M5, M6, M12, M28, and M31-M34) in the feces were detected. When orally administered to conventional rats, neomangiferin was initially metabolized into mangiferin, and the subsequent metabolic pathways were similar to those in conventional rats after mangiferin was orally administered. Our in vivo metabolic analysis indicated that neomangiferin is metabolized via an intermediate mangiferin to other final metabolites.
After oral administration of neomangiferin to pseudo-germ-free rats, the metabolic pathways of neomangiferin were similar to those in conventional rats after its intravenous injection administration. The parent compound also appeared in the plasma and urine. In addition, 2 metabolites (M5, M21) in the plasma, 6 metabolites (M1-M5, M21) in the urine, and 5 metabolites (M5, M10, M12, M14, M21) in the feces were detected. Deglycosylation, methylation, glucuronidation and sulfation were proposed to be the predominant metabolic pathways of neomangiferin in pseudo-germ-free rat.
In this study, a simple, accurate, and selective method was established to determine neomangiferin and its metabolite mangiferin in rat plasma simultaneously. The proposed method was applied successfully to conduct a pharmacokinetic analysis of neomangiferin orally and intravenously administered to rats. Pharmacokinetic results revealed that neomangiferin was absorbed and eliminated rapidly in vivo. Neomangiferin was also partly transformed to mangiferin rapidly post-dosing and exhibited poor bioavailability (only 0.32%). This poor bioavailability may be partially attributed to the low absorption and extensive metabolism of neomangiferin. Furthermore, 33 metabolites of neomangiferin in rats were identified for the first time. Neomangiferin underwent rapid and extensive phases I and II metabolic processes, such as deglycosylation, dehydroxylation, methylation, glycosylation, glucuronidation, and sulfation, after this component was orally administered to rats. In general, the pharmacokinetic and metabolic profiles, including poor bioavailability, high absorption and elimination rates, easy biotransformation, and some metabolic pathways, of neomangiferin were similar to those of mangiferin. This resemblance may be ascribed to the comparable chemical structures of these compounds. However, these pharmacokinetic characteristics may hinder the development of neomangiferin as a new drug candidate. Our findings could provide critical information to promote further exploration and enhancement of neomangiferin.
We thank the State Key Program of National Natural Science Foundation of China (Grant No. 81030065) and the National Science and Technology Major Project (Grant Nos. 2009ZX09301-001, 2009ZX09102-121, 2009ZX09501-030, 2012ZX09301001-001) for providing financial support.